Precigen (NASDAQ:PGEN) CEO Helen Sabzevari Sells 346,836 Shares of Stock

Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 346,836 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the sale, the chief executive officer owned 3,768,872 shares in the company, valued at $22,198,656.08. This represents a 8.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Sabzevari also recently made the following trade(s):

• On Thursday, May 28th, Helen Sabzevari sold 119,250 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total transaction of $519,930.00.

Precigen Trading Down 7.9%

Precigen stock opened at $5.25 on Thursday. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. Precigen, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $6.04. The stock has a market cap of $1.87 billion, a P/E ratio of -4.45 and a beta of 1.00. The firm’s fifty day moving average price is $4.43 and its 200-day moving average price is $4.22.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. Equities research analysts forecast that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PGEN. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Citizens Jmp increased their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. HC Wainwright lifted their price objective on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. State of Wyoming purchased a new stake in shares of Precigen in the 1st quarter valued at $27,000. NBC Securities Inc. purchased a new stake in Precigen during the fourth quarter valued at about $38,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Precigen during the third quarter valued at about $39,000. Royal Bank of Canada increased its holdings in shares of Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,426 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in shares of Precigen in the 3rd quarter valued at about $41,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.